Antibody-based therapeutics to watch in 2011. - Wikidata - awgldk - TriplyDB

Antibody-based therapeutics to watch in 2011.

Antibody-based therapeutics to watch in 2011.

http://www.wikidata.org/entity/Q34570079

about

Vedolizumab for the treatment of ulcerative colitis and Crohn's disease Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells Biologics in organ transplantation Pharmacokinetic/pharmacodynamic modeling in inflammation Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs Monoclonal antibodies for the treatment of cancer Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis Antibodies to watch in 2015 Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity Low level sequence variant analysis of recombinant proteins: an optimized approach Flexible antibodies with nonprotein hinges.An innovative approach for the characterization of the isoforms of a monoclonal antibody product Identification of Eps15 as antigen recognized by the monoclonal antibodies aa2 and ab52 of the Wuerzburg Hybridoma Library against Drosophila brain.The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen CD6 as a therapeutic target in autoimmune diseases: successes and challenges.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Generation and analysis of the improved human HAL9/10 antibody phage display libraries.Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab Therapeutic antibodies against cancer.The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Soluble monomeric IgG1 Fc.Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on Monoclonal antibodies and toxins--a perspective on function and isotype.Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.Electrospray ionization-ion mobility spectrometry identified monoclonal antibodies that bind exclusively to either the monomeric or a dimeric form of prostate specific antigen Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines.Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas Target Therapy in Hematological Malignances: New Monoclonal Antibodies.FAT1: a potential target for monoclonal antibody therapy in colon cancer.Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.

P2860

Q24630083-AE8FDB7C-F6F7-4B7E-BC79-A129D9B2C6C7 Q26752768-36AD2D0F-917E-4026-88D9-A94A83B26768 Q26772699-AB8929CC-5864-44CF-BA1F-6FE88831AD55 Q26829578-80C71BD2-ACF2-427C-9A71-D4B216C19B26 Q26830621-886E4557-D5EB-43D8-B5CE-CBE50794D217 Q26849777-52629993-180F-4FDD-A0BA-AB65FFAD7FD7 Q26863621-AC67E258-325C-490C-B50A-66A804E2E8D8 Q27025966-68E4546E-8BA2-4DCB-A46D-D4775292EFD2 Q27678647-3D257B35-E2DD-4788-8D84-63968445F3CE Q28080984-0A9DB3BB-EE8F-4058-BA7F-9B3A396C6BCE Q28253501-6BFFFE65-86FA-490D-B740-5289A45D9BC6 Q28658712-693925C6-885B-4F71-89E3-85E710D02C13 Q28727418-471814A8-DD2D-402A-B94F-BA8DDE7894BB Q30409337-B95D6DE2-2990-4F02-9ACC-48AF18681494 Q34084985-B277D612-7EA8-4C24-A88C-4AE70E6E40B9 Q34113731-EAD19E71-CDBA-456B-80B7-753D0AF89174 Q34212743-613F2126-CB7C-4C5A-955B-68922D1ACD7B Q34337963-083D4E24-4FF1-4364-B4E2-A28FBE8DF39C Q34530196-B033E4A2-2386-4DB0-BBF1-8DC5A915345B Q35001563-9B66C600-874A-4E5D-8284-A6DA854EFF94 Q35459059-438F6B64-2A38-493D-9EEE-A12EF5543492 Q35608279-95BF7192-67C1-49C4-A07B-D84C2C6A095B Q35662815-F3BEED46-D60F-47BE-A47B-4BDD24DA5DB8 Q35908498-F557387D-806A-47D0-8B86-DEB732C3E66D Q35938926-4304670C-4032-4D5B-BAD6-AC8C54469FD3 Q35992488-EC3C264A-4216-4DB8-89C4-A0954A7765F9 Q36003820-EF0FA633-C1F3-482E-A705-628773613484 Q36050013-F4D17054-2EBF-4DB2-B274-42BCA629DA0E Q36099489-51530801-7F28-4CD9-A6B3-0DA759204861 Q36108119-A47DEB78-587F-42E6-A329-D8D256B8BFAD Q36126960-5251DD90-5219-4CA6-9777-A6532948EF08 Q36127055-BFE30175-4E1A-451D-A2A6-CDAEA88F21F7 Q36145292-8037BC68-786C-41D5-9C63-97C85359A96A Q36372353-7F38C861-3621-46FD-8043-5FF36AB3A703 Q36588710-7D183686-D6E5-47CF-9CD4-AAC6B275755E Q36775313-BE19F8BB-1BB3-4EBC-B845-53363379285A Q36979140-42BB5D88-2B13-495B-9872-6A3BB610C88E Q37061340-1E3EBA9D-969B-44F0-8D20-A975512852F8 Q37132068-544B194E-ADD1-4242-955F-3627D5A84E23 Q37593702-CF04A3A8-B979-4FF9-9BB3-99CF3B5030D0

P2860

Antibody-based therapeutics to watch in 2011.

http://www.wikidata.org/entity/Q34570079

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Antibody-based therapeutics to watch in 2011.

@ast

Antibody-based therapeutics to watch in 2011.

@en

Antibody-based therapeutics to watch in 2011.

@nl

type

label

Antibody-based therapeutics to watch in 2011.

@ast

Antibody-based therapeutics to watch in 2011.

@en

Antibody-based therapeutics to watch in 2011.

@nl

prefLabel

Antibody-based therapeutics to watch in 2011.

@ast

Antibody-based therapeutics to watch in 2011.

@en

Antibody-based therapeutics to watch in 2011.

@nl

P1433

Q34570079-EDBEDA68-8620-40A2-AAA5-58552F514FFF

P1476

Q34570079-A44E996F-3B27-4C10-B038-953392C320CA

P2093

Q34570079-B6B8D4A4-81BA-45A7-B4A6-8332816309CD

P2860

Q34570079-0341ABC4-05AA-462E-8600-FC95327C2133

Q34570079-07306F89-A9AC-4DBD-812E-4DF36CC50004

Q34570079-08614483-27DA-45B4-8ACC-A0DD567DA30E

Q34570079-08A5E719-4C12-4AC2-AFFD-FB99F337EFAE

Q34570079-09728DC3-F46E-448A-8113-0C3687A3115E

Q34570079-09D6291D-ADEA-4738-80AF-59924D6B8ECF

Q34570079-0C31845A-550B-4D69-8C1F-AEDDC47C38A0

Q34570079-124AA9E3-5A08-4EC5-9E4B-C85BB24A802E

Q34570079-1BAAE81C-4D90-42FA-B6D9-9ED059FC4674

Q34570079-1D518EBB-096E-4BFD-A393-26F36AE5B189

P304

Q34570079-30DC5033-9F3E-41C8-9A71-58D123ECA0A4

P31

Q34570079-8C51F606-8AA8-4118-B962-34058991C0A7

Q34570079-90069240-bd65-4671-ba5a-8349953e8080

P356

Q34570079-91D2ACF8-C04D-44B1-9780-88142E1880FF

P433

Q34570079-26D26DF8-F509-4C8F-ABEF-698E650995CD

P478

Q34570079-8726084C-578E-4A79-A7AF-C2C8DE12B4BE

P577

Q34570079-26A98CED-DCC2-4FF5-95B3-D2F32AC46C80

P5875

Q34570079-72D8C33D-FBAF-48A9-8660-EA043B403FDE

P698

Q34570079-D9606051-39BF-45CD-AFCB-08D85F20D938

P921

Q34570079-01E0F6AF-1F8C-40C3-8BD9-BF34F4BA74C7

P932

Q34570079-5FAFD169-9601-4031-A713-BCD8B5A4E427

P356

P1433

Monoclonal Antibodies

P1476

Antibody-based therapeutics to watch in 2011.

@en

P2093

Janice M Reichert

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 blockade: therapeutic potential in cancer treatments

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Catumaxomab: clinical development and future directions

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Antibodies to watch in 2010

P304

76-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.3.1.13895

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47679523

http://www.w3.org/2001/XMLSchema#string

P698

21051951

http://www.w3.org/2001/XMLSchema#string

P921

P932

3038014

http://www.w3.org/2001/XMLSchema#string